Lexington, MA — October 16, 2025 — Leads & Copy — Agenus Inc. (Nasdaq: AGEN) will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading experts on recent clinical progress and expanding international access for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL).
The session will be moderated by Garo Armen, PhD, Founder, Chairman, and CEO, and conclude with a live Q&A. Michael S. Gordon, MD, HonorHealth Research Institute, will discuss results from his oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025, featuring data from over 400 patients treated with BOT/BAL across multiple refractory solid tumors.
Alexander M.M. Eggermont, MD, PhD, world-renowned immuno-oncologist and former Director General of the Gustave Roussy Cancer Center in France, will provide perspective on the French AAC program and its implications for oncologists and patients living with refractory MSS colorectal cancer.
This session marks the second in Agenus’ 2025 Stakeholder Briefing Series, following the August event highlighting corporate strategy, clinical milestones, and the launch of the global Phase 3 BATTMAN trial. A third session will follow in November, continuing the dialogue on BOT/BAL’s progress and corporate milestones.
Webcast Link: https://riverside.fm/studio/agenus-presentation Pre-registration is not required.
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.
Contact:
Garo Armen, PhD
Founder, Chairman, and CEO
Source: Agenus Inc.
